Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor News
Share Price / Index
June 20, 2025
Not intended for U.S. and UK Media
CHMP recommends third indication for Bayer’s Nubeqa™ (darolutamide) for patients with advanced prostate cancer
June 17, 2025
Not intended for US and UK Media
Bayer files for approval of gadoquatrane in the U.S.
June 05, 2025
Not intended for U.S. and UK Media – CONFIDENCE Phase II study results presented at 62nd ERA Congress:
Simultaneous treatment start with Finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes
Discover More
